glp 1 alcoholism IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 Medications and Alcohol: A

Personalized medical support can prevent or mitigate these symptoms, improving adherence and the overall success of the therapy

Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28 percent of their body weight - a substantial step up in...

Compare 5 ways to save on Vyvanse with or without insurance

Reduced calorie intake can often lead to lower micronutrient intake

Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, announced today a major

Epidemiological studies suggest a higher incidence of PD among individuals with T2DM, with growing evidence that diabetes may accelerate the onset and progression of motor and cognitive symptoms